NASDAQ:FWBI First Wave BioPharma (FWBI) Stock Price, News & Analysis → Bigger Than NVIDIA? (From Behind the Markets) (Ad) Free FWBI Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range$2.60▼$4.6352-Week Range N/AVolume56,500 shsAverage Volume212,944 shsMarket Capitalization$7.34 millionP/E RatioN/ADividend YieldN/APrice Target$36.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get First Wave BioPharma alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About First Wave BioPharma Stock (NASDAQ:FWBI)First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.Read More Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> FWBI Stock News HeadlinesMay 22, 2024 | finance.yahoo.comEntero Therapeutics to Present Corporate Update at 2024 BIO International ConventionMay 20, 2024 | finance.yahoo.comEntero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) ConferenceMay 16, 2024 | finance.yahoo.comFirst Wave BioPharma Changes Name to Entero TherapeuticsMay 15, 2024 | investorplace.comFWBI Stock Earnings: First Wave BioPharma Beats EPS for Q1 2024May 10, 2024 | globenewswire.comFirst Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-MarketMay 9, 2024 | globenewswire.comFirst Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness MonthApril 24, 2024 | globenewswire.comFirst Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, NutrientsApril 17, 2024 | finance.yahoo.comFirst Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap ShowcaseApril 15, 2024 | globenewswire.comFirst Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders ConferenceApril 5, 2024 | investing.comFirst wave BioPharma CEO sells shares to cover tax obligationsMarch 21, 2024 | investing.comFirst wave BioPharma CEO sells shares worth over $9,000March 21, 2024 | investing.comFirst wave BioPharma CFO sells shares worth over $5,500March 18, 2024 | globenewswire.comFirst Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) ConferenceMarch 14, 2024 | investorplace.comWhy Is First Wave BioPharma (FWBI) Stock Up Today?March 14, 2024 | msn.comFirst Wave BioPharma Completes Merger Deal With ImmunogenX Adding Phase 3-Ready Candidate For Celiac DiseaseMarch 14, 2024 | globenewswire.comFirst Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical PipelineMarch 5, 2024 | finance.yahoo.comFirst Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth ConferenceMarch 5, 2024 | globenewswire.comFirst Wave BioPharma to Participate In ‘Fireside Chat' at the 36th Annual Roth ConferenceMarch 4, 2024 | marketwatch.comFirst Wave BioPharma Shares Drop 25% After Direct Offering PricesMarch 4, 2024 | msn.comFirst Wave Biopharma to raise about $4M of proceeds in direct offeringMarch 4, 2024 | finance.yahoo.comFirst Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct OfferingFebruary 13, 2024 | finance.yahoo.comFirst Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024January 23, 2024 | finance.yahoo.comFirst Wave BioPharma to Present at the DealFlow MicroCap ConferenceJanuary 22, 2024 | benzinga.comThis BioPharma Could Be First To Market With Its Celiac Therapy – Phase 3 Clinical Trials To Commence In 2024January 8, 2024 | msn.comFirst Wave BioPharma files to sell 1.76M for holdersSee More Headlines Receive FWBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for First Wave BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2021Today6/17/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FWBI CUSIPN/A CIK1604191 Webwww.azurrx.com Phone(561) 589-7020FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$36.00 Low Stock Price Target$36.00 Potential Upside/Downside+1,116.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-102.83% Return on Assets-22.74% Debt Debt-to-Equity Ratio0.40 Current Ratio1.21 Quick Ratio1.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.54 per share Price / Book0.45Miscellaneous Outstanding Shares2,480,000Free Float2,463,000Market Cap$7.34 million OptionableNot Optionable Beta1.28 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. James R. Sapirstein M.B.A. (Age 63)R.Ph., CEO & Chairman Comp: $906.2kMs. Sarah Romano CPA (Age 43)Chief Financial Officer Comp: $624.88kDr. Jack A. Syage Ph.D. (Age 69)President, COO & Director Ms. Amy Chandler-Skerkis (Age 55)Vice President of Regulatory Affairs, QA & Compliance Mr. Martin Krusin M.B.A.Senior Vice President of Corporate DevelopmentKey CompetitorsBolt BiotherapeuticsNASDAQ:BOLTBioVieNASDAQ:BIVIImmunoPrecise AntibodiesNASDAQ:IPABiora TherapeuticsNASDAQ:BIORSpruce BiosciencesNASDAQ:SPRBView All CompetitorsInsidersJames SapirsteinSold 174 sharesTotal: $736.02 ($4.23/share)Sarah RomanoSold 75 sharesTotal: $317.25 ($4.23/share)James SapirsteinSold 1,887 sharesTotal: $9,359.52 ($4.96/share)Sarah RomanoSold 1,120 sharesTotal: $5,555.20 ($4.96/share)James SapirsteinSold 166 sharesTotal: $697.20 ($4.20/share)View All Insider Transactions FWBI Stock Analysis - Frequently Asked Questions Should I buy or sell First Wave BioPharma stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for First Wave BioPharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FWBI shares. View FWBI analyst ratings or view top-rated stocks. What is First Wave BioPharma's stock price target for 2024? 2 equities research analysts have issued 1 year price targets for First Wave BioPharma's stock. Their FWBI share price targets range from $36.00 to $36.00. On average, they predict the company's stock price to reach $36.00 in the next year. View analysts price targets for FWBI or view top-rated stocks among Wall Street analysts. When is First Wave BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our FWBI earnings forecast. How were First Wave BioPharma's earnings last quarter? First Wave BioPharma, Inc. (NASDAQ:FWBI) issued its earnings results on Sunday, November, 14th. The company reported ($13,734.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3,318.00) by $10,416.00. When did First Wave BioPharma's stock split? First Wave BioPharma's stock reverse split on the morning of Monday, December 18th 2023. The 1-20 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of First Wave BioPharma? Shares of FWBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FWBI) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Wave BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share First Wave BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.